See more : Ginko International Co., Ltd. (8406.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Pulse Biosciences, Inc. (PLSE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulse Biosciences, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Rykadan Capital Limited (2288.HK) Income Statement Analysis – Financial Results
- Millrock Resources Inc. (MRO.V) Income Statement Analysis – Financial Results
- Montanaro UK Smaller Companies Investment Trust PLC (MTU.L) Income Statement Analysis – Financial Results
- Hansol Paper Co., Ltd. (213500.KS) Income Statement Analysis – Financial Results
- freenet AG (FNTN.HM) Income Statement Analysis – Financial Results
Pulse Biosciences, Inc. (PLSE)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.pulsebiosciences.com
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.21M | 11.94M | 1.97M | 665.00K | 666.00K | 665.00K | 665.00K | 665.00K | 0.00 | 0.00 |
| Gross Profit | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | -665.00K | -665.00K | -665.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -1,606.29% | -38.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.80M | 20.84M | 28.64M | 26.44M | 24.96M | 17.25M | 9.65M | 5.99M | 2.58M | 44.57K |
| General & Administrative | 15.78M | 13.96M | 19.07M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Selling & Marketing | 0.00 | 12.02M | 14.75M | 7.26M | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.78M | 25.97M | 33.82M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 665.00K | 666.00K | -28.00K | 665.00K | 665.00K | 665.39K | 0.00 |
| Operating Expenses | 43.57M | 46.81M | 62.46M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Cost & Expenses | 43.57M | 58.76M | 64.43M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Interest Income | 0.00 | 263.00K | 646.00K | 114.00K | 983.00K | 446.00K | 247.00K | 68.00K | 0.00 | 0.00 |
| Interest Expense | 1.36M | 448.00K | 646.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.21M | 1.36M | 1.15M | 1.10M | 1.16M | 1.31M | 1.00M | 759.00K | 716.98K | 200.57K |
| EBITDA | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | -36.65M | -24.57M | -8.83M | -3.75M | -108.00K |
| EBITDA Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | -37.96M | -25.81M | -9.59M | -4.47M | -308.57K |
| Operating Income Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.36M | -448.00K | -646.00K | 114.00K | 983.00K | 418.00K | 247.00K | 68.00K | 0.00 | -396.00K |
| Income Before Tax | -42.21M | -58.51M | -63.66M | -49.85M | -46.97M | -37.55M | -25.57M | -9.52M | -4.47M | -514.29K |
| Income Before Tax Ratio | 0.00% | -8,357.86% | -4,489.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 448.00K | -500.00K | -114.00K | -983.00K | -28.00K | -912.00K | -94.00K | -1.66M | 39.43K |
| Net Income | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M | -37.55M | -25.57M | -9.52M | -2.81M | -474.86K |
| Net Income Ratio | 0.00% | -8,421.86% | -4,454.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| EPS Diluted | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Weighted Avg Shares Out | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
| Weighted Avg Shares Out (Dil) | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of...
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Officer Mike Koffler - Vice President, Finance Conference Call Participants...
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30,...
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical...
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024
Pulse Biosciences (NASDAQ: PLSE ) just reported results for the second quarter of 2024. Pulse Biosciences reported earnings per share of -20 cents.
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffler - VP of Finance Conference Call Participants Anthony Petrone...
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced plans to participate in two upcoming investor conferences. 9th Annual Needham MedTech & Diagnostics...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The investigation seeks to determine whether Pulse Bioscience's directors breached their fiduciary...
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has commenced its previously announced rights offering of up to...
Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024...
Source: https://incomestatements.info
Category: Stock Reports